Brandon Bernard, MD, MPH

Among other things, a medical oncologist. Interests: RWD, disparities research, clinical trials. Views my own & ≠ medical advice. He/him.

[Anis Hamid @anis_a_hamid]

EFS not a surrogate for OS in M0 prostate cancer treated by RT. Great work @Wanling50578056 @Merregan @ChrisSweens1 #ICECaP @PCF_Science Continuing to inform trial design in this space. https://t.co/y2KZmydrZk

[Brandon Bernard, MD, MPH @DrBrandonB]

Some practical tips n tricks for clinic. Thx @Lauren_J_MacK for passing along! https://t.co/AdnntZosOX

[Brandon Bernard, MD, MPH @DrBrandonB]

Relatable? 🤦🏼‍♂️ https://t.co/BboNMXcxxW

[Brandon Bernard, MD, MPH @DrBrandonB]

The time is now to #FlattenTheCurve. Success depends on proactive, aggressive approach with complete buy-in. #SocialDistancing is bare minimum. Personally, I will try to avoid all cafes, restaurants, the gym, etc. I strongly urge all to consider the same #COVIDー19 #coronavirus

[Brandon Bernard, MD, MPH @DrBrandonB]

@g_develasco @MDAndersonNews You certainly have to wonder!

[Brandon Bernard, MD, MPH @DrBrandonB]

@DrRanaMcKay @DrChoueiri @Dominick_Bosse @Cold_Steel_1970 Excellent work & agree with this strategy as a 'litmus test' to see which int risk pts you may consider for CN down the line. Have also used for non-met disease if poor GFR & hopeful to use partial nephrectomy 👍

[Brandon Bernard, MD, MPH @DrBrandonB]

Fantastic work by @Dominick_Bosse and colleagues. Valuable data to factor into treatment approach algorithm esp if considering CN as part of the package

[Dominick Bossé, MD MPH @Dominick_Bosse]

Check out our paper on primary RCC tumour response to systemic therapy in @EUplatinum — highly relevant in the CARMENA era. ORR 28% in primary mass, hematuria rates low. Need more data w IO @DrRanaMcKay @DrChoueiri @lalaniMD @Wanling50578056 @DanaFarber https://t.co/qQA9ECP6rT

[Brandon Bernard, MD, MPH @DrBrandonB]

Great to attend @ProstateCancerC Wake Up Call Breakfast today. Great conversations & huge promise to improve outcomes in #prostatecancer! @P_Coleridge @frbenard @Drew_Green @Mike_Killeen

[Brandon Bernard, MD, MPH @DrBrandonB]

Thank you ASCO Direct Highlights Denver & @TotalHealthConf for the opportunity to discuss the most impactful #ProstateCancer abstracts from #ASCO19! Lots of great advancements to move patient care forward

[Total Health™ @TotalHealthConf]

Dr. Brandon Bernard of University of Colorado talking about abstracts from #ASCO19

--> https://t.co/MJ5hQMhoAX

@belowthebelt_md #MetastaticCastrationResistantProstateCancer #totalhealthconf

[Brandon Bernard, MD, MPH @DrBrandonB]

@PGrivasMDPhD @ASCO @SeattleCCA @fredhutch @uwurology @ASCOPres Great to meet you in person and share the stage! Was a lot of fun and look forward to the next time

[Brandon Bernard, MD, MPH @DrBrandonB]

@jgong15 @g_develasco @ASCO @ASCOPost @CedarsSinai @CedarsUroOncol @jacobadashek @PauloBergerot @NazliDizman @manuelmaiamd @crisbergerot @montypal @TDorffOnc @ChrisSweens1 @Oncoblogg @sogug1 One way of thinking of it - though in 90% it IS the intensification strategy. Unfortunately N too low to see if effect is additive / synergistic with doce. Maybe ENZAMET will unveil more...

[Brandon Bernard, MD, MPH @DrBrandonB]

@g_develasco @jgong15 @ASCO @ASCOPost @CedarsSinai @CedarsUroOncol @jacobadashek @PauloBergerot @NazliDizman @manuelmaiamd @crisbergerot @montypal @TDorffOnc @ChrisSweens1 @Oncoblogg @sogug1 Also I think TITAN had to be </= 6 mo ADT to enroll and if doing doce x 6 makes for a pretty tight window

[Brandon Bernard, MD, MPH @DrBrandonB]

@g_develasco @jgong15 @ASCO @ASCOPost @CedarsSinai @CedarsUroOncol @jacobadashek @PauloBergerot @NazliDizman @manuelmaiamd @crisbergerot @montypal @TDorffOnc @ChrisSweens1 @Oncoblogg @sogug1 Prob started enrolling prior to CHAARTED presentation / publication / guideline adoption.

[Brandon Bernard, MD, MPH @DrBrandonB]

@g_develasco It's okay. Galactico Beckham is his idol 😂👏

[ANZUP @ANZUPtrials]

Very proud & excited to see our ENZAMET trial featured in 2019 ASCO Plenary session. Congratulations to the authors, investigators & trial participants. @ANZUPtrials @ChrisSweens1 @Prof_IanD @DanaFarber @TrialsCentre @cancertrials_ie @CDNCancerTrials @CancerAustralia #ASCO19

[Christopher Sweeney, MBBS @ChrisSweens1]

Thanks to all the teams from Australia, New Zealand, Canada, @DanaFarber, Ireland and UK who all supported the #ENZAMET trial. Thanks also to @ASCO for choosing it as a plenary presentation based on the clinical practice & biology informing data for mHSPC @ANZUPtrials @Uromigos

[Scott Tagawa @DrScottTagawa]

Initial look at selected genes from WES of tumor with relationship to outcome from PSMA-TRT in #prostatecancer, perhaps not too surprising BRCA2 favorable TP53 unfavorable #GU19 - look forward to further analyses in larger dataset with @PCF_Science and @CDMRP funding

[Elizabeth Plimack MD @ERPlimackMD]

Dr. Lotan @UTSWUrology reminds us that many pts with localized muscle invasive #bladdercancer are higher stage than we think. Therefore we are missing pts who may beneft from neoadj systemic rx. Biomarkers/subtypes are poised to help our ability to identfy these pts #GU19 #blcsm

[Brandon Bernard, MD, MPH @DrBrandonB]

@g_develasco Hard to say. Total population in ARCHES doing quite well, incl placebo arm & even with ~2/3 being high volume. Compare with LATITUDE where ~1/2 in placebo dead at 3 yrs. Maybe less risky pop OR doce pulled OS up in placebo arm. Plus short F/U...

[Brandon Bernard, MD, MPH @DrBrandonB]

Love @Prof_IanD's focus on CE in his abst discussion - needs to be a consideration in ALL data interpretation. BUT now what? XRT to primary for LV dz? Doce for HV? Abi + XRT for N0/N1? Let alone sequential a la #ARCHES TBC... #GU19